Arkolith/Insider Trading/RARE/Form 4

Huizenga Theodore Alan

SVP, Chief Accounting OfficerUltragenyx Pharmaceutical Inc. (RARE) · full profile →Form 4 · filed Mar 4, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$41K
Net Open-Market Flow
-$41K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2025Sell(S)967$42.10$41K50K
Mar 3, 2025Tax withholding(F)141$42.92$6K50K
Mar 1, 2025Grant(A)9K—$051K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 1, 2025Grant(A)6K—$06K

Transaction Codes

S
Open-market sale
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-032764) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML